Dashboard
Manage Tickers

ABOS Acumen Pharmaceuticals, Inc.

Nasdaq acumenpharm.com


$ 2.07 $ -0.10 (-4.69 %)    

Friday, 17-Oct-2025 19:23:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.03
$ 2.13
$ 2.06 x 255
$ 2.07 x 51
$ 2.00 - $ 2.17
$ 0.86 - $ 3.36
193,737
na
122.96M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/25/2025 17:06:09

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...

b-of-a-securities-maintains-buy-on-acumen-pharmaceuticals-lowers-price-target-to-9
B of A Securities Maintains Buy on Acumen ...
08/25/2025 16:53:29

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price targe...

acumen-pharmaceuticals-q2-eps-068-misses-052-estimate
Acumen Pharmaceuticals Q2 EPS $(0.68) Miss...
08/12/2025 11:00:57

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate...

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

acumen-pharmaceuticalss-earnings-a-preview
Acumen Pharmaceuticals's Earnings: A Preview
08/11/2025 19:03:22

watching-acumen-pharmaceuticals-shares-move-higher-traders-circulate-daily-mail-article-titled-scientists-make-huge-dementia-breakthrough-as-they-reveal-new-jab-which-could-prevent-alzheimers
Watching Acumen Pharmaceuticals; Shares Mo...
07/30/2025 14:50:37

https://www.dailymail.co.uk/health/article-14954333/dementia-jab-breakthrough-Alzheimers.html

acumen-pharmaceuticals-presents-studies-showing-utility-of-ptau217-assay-in-screening-for-phase-2-alzheimers-disease-trial-and-validates-sabirnetug-oligomer-selectivity
Acumen Pharmaceuticals Presents Studies Sh...
07/28/2025 12:08:24

acumen-pharmaceuticals-agrees-with-jcr-pharmaceuticals-to-develop-an-oligomer-targeted-enhanced-brain-delivery-therapy-for-alzheimers-jcr-will-receive-an-upfront-payment-and-will-be-eligible-for-an-additional-option-payment-should-acumen-exercise-its-exclusive-option-to-develop-up-to-two-development-candidates
Acumen Pharmaceuticals Agrees With JCR Pha...
07/15/2025 11:02:56

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR'...

acumen-pharmaceuticals-to-present-at-alzheimers-association-international-conference-jul-28-and-29
Acumen Pharmaceuticals To Present At Alzhe...
07/10/2025 12:13:01

citigroup-initiates-coverage-on-acumen-pharmaceuticals-with-buy-rating-announces-price-target-of-4
Citigroup Initiates Coverage On Acumen Pha...
06/17/2025 11:34:51

Citigroup analyst Geoff Meacham initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announces P...

acumen-pharmaceuticals-q1-gaap-eps-048-beats-054-estimate
Acumen Pharmaceuticals Q1 GAAP EPS $(0.48)...
05/13/2025 11:00:59

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate o...

Core News & Articles
Earnings Scheduled For May 13, 2025
05/13/2025 08:32:43

a-preview-of-acumen-pharmaceuticalss-earnings
A Preview Of Acumen Pharmaceuticals's Earn...
05/12/2025 18:10:32

acumen-pharmaceuticals-presented-extended-results-from-its-validated-research-use-plasma-ptau217-assay-to-screen-potential-participants-in-the-ongoing-phase-2-altitude-ad-trial-of-sabirnetug
Acumen Pharmaceuticals Presented Extended ...
04/02/2025 11:05:03

ubs-maintains-buy-on-acumen-pharmaceuticals-lowers-price-target-to-4
UBS Maintains Buy on Acumen Pharmaceutical...
03/28/2025 13:36:18

UBS analyst Colin Bristow maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $6 to $4.

hc-wainwright--co-maintains-buy-on-acumen-pharmaceuticals-lowers-price-target-to-11
HC Wainwright & Co. Maintains Buy on Acume...
03/28/2025 12:35:14

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price t...

acumen-pharmaceuticals-fy-2024-eps-171-misses-155-estimate
Acumen Pharmaceuticals FY 2024 EPS $(1.71)...
03/27/2025 11:03:43

Acumen Pharmaceuticals (NASDAQ:ABOS) reported FY 2024 EPS $(1.71) Misses $(1.55) Estimate.

earnings-scheduled-for-march-27-2025
Earnings Scheduled For March 27, 2025
03/27/2025 08:32:15

preview-acumen-pharmaceuticalss-earnings
Preview: Acumen Pharmaceuticals's Earnings
03/26/2025 19:01:56

acumen-pharmaceuticals-completes-enrollment-in-altitude-ad-phase-2-clinical-trial-of-acu193-in-early-alzheimers-disease-plans-to-report-topline-results-including-efficacy-and-safety-data-in-late-2026
Acumen Pharmaceuticals Completes Enrollmen...
03/26/2025 12:02:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION